Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
NCT05077969 · Leidos Life Sciences · PHASE2 · terminated · last registry update 2024-07-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment” | – | Registry record, Leidos Life Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HRH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-03Also stopped (withdrawn): University of Miami, Acetaminophen + Celebrex (NCT05965492)
- 2025-05-06Results posted on the registry: University of Chicago, nab-paclitaxel + Carboplatin (NCT03107182)
- 2025-02-25Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), elotuzumab + placebo for elotuzumab (NCT04918147)
- 2025-02-06Also stopped (terminated): Bristol-Myers Squibb, BMS-986465 + Pegasys (NCT06144697)
- 2025-01-30Phase 3 first posted: The University of Texas Medical Branch, Galveston, Famotidine and 4% topical cromolyn sodium (NCT06801626)
- 2025-01-17Results posted on the registry: Zimmer Biomet, a drug against HRH2 (NCT03073941)
- 2024-11-14Results posted on the registry: Pfizer, Abrocitinib tablet + Abrocitinib Suspension F1 (NCT04903093)
- 2024-10-30Results posted on the registry: Eli Lilly and Company, Selpercatinib + Ranitidine (NCT05338502)
- 2024-10-24Also stopped (withdrawn): Stephen Ruedrich, Valbenazine Oral Capsule (NCT06107829)
- 2024-08-13Also stopped (withdrawn): University of California, Los Angeles, a drug against HRH2 (NCT05629715)
- 2024-08-09Results posted on the registry: University of Washington, Famotidine 20 MG (NCT03554291)
- 2024-04-16Results posted on the registry: Ultragenyx Pharmaceutical Inc, UX053 + Antipyretic (NCT04990388)
- 2024-04-16Also stopped (terminated): Ultragenyx Pharmaceutical Inc, UX053 + Antipyretic (NCT04990388)
- 2024-02-16Results posted on the registry: Oxford University Hospitals NHS Trust, a drug against HRH2 (NCT05935878)
- 2024-02-02Results posted on the registry: National Cancer Institute (NCI), LMB-100 + ipilimumab (NCT04840615)
- 2024-02-02Also stopped (terminated): National Cancer Institute (NCI), LMB-100 + ipilimumab (NCT04840615)
- 2024-01-31Results posted on the registry: Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-31Also stopped (terminated): Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2023-12-01Results posted on the registry: NYU College of Dentistry, a drug against HRH2 (NCT04778709)
- 2023-12-01Also stopped (terminated): NYU College of Dentistry, a drug against HRH2 (NCT04778709)
- 2023-11-28Results posted on the registry: National Cancer Institute (NCI), Moxetumomab Pasudotox-tdfk + Rituximab (NCT03805932)
- 2023-10-30Results posted on the registry: Ohio State University, a drug against HRH2 (NCT04350827)
- 2023-10-10Also stopped (withdrawn): Leidos Life Sciences, Famotidine + Celecoxib (NCT05085574)
- 2023-07-28Phase 3 first posted: University of Miami, Acetaminophen + Celebrex (NCT05965492)
- 2023-07-14Phase 3 first posted: Emory University, Cetirizine + Famotidine (NCT05946551)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision